Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin

Peripheral T-cell lymphomas (PTCLs) are a rare and heterogenous group of hematological malignancies involving T or NK cells. PTCLs are generally associated with an aggressive course and poor prognosis. Pralatrexate (PDX) is the first FDA-approved agent for the treatment of refractory/recurrent PTCL....

Descripción completa

Detalles Bibliográficos
Autores principales: Kitazume, Koichi, Akagawa, Yuri, Wada, Sachie, Suzuki, Takayuki, Fujita, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696769/
https://www.ncbi.nlm.nih.gov/pubmed/31427947
http://dx.doi.org/10.1159/000501070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696769/
https://www.ncbi.nlm.nih.gov/pubmed/31427947
http://dx.doi.org/10.1159/000501070

Ejemplares similares